OmniAb, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 05:03 pm EDT
Share
OmniAb, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 6.95 million compared to USD 7.2 million a year ago. Net loss was USD 14.73 million compared to USD 10.28 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.12 a year ago.
For the six months, revenue was USD 23.87 million compared to USD 16.82 million a year ago. Net loss was USD 20.83 million compared to USD 16.56 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.2 a year ago.
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Companyâs OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.